X0206 3 2019-12-27 0 0001740547 Urovant Sciences Ltd. UROV 0001798550 Sumitomo Chemical Co., Ltd. 27-1 SHINKAWA 2-CHOME CHUO-KU, TOKYO M0 104-8260 JAPAN 0 0 1 0 0001446601 Dainippon Sumitomo Pharma Co Ltd 6-8 DOSHOMACHI 2-CHOME CHUO-KU, OSAKA M0 541-0045 JAPAN 0 0 1 0 0001798244 Sumitovant Biopharma Ltd. 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FLOOR LONDON X0 SW1Y 4LB UNITED KINGDOM 0 0 1 0 Common Stock 22860013 I See footnote Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 22,860,013 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Sumitomo Chemical Co., Ltd. By Yoshiaki Oda Managing Executive Officer, Corporate Business Development Department /s/ Yoshiaki Oda 2020-01-03 Sumitomo Dainippon Pharma Co., Ltd. By Hiroyuki Baba Senior Executive Officer, Global Corporate Strategy /s/ Hiroyuki Baba 2020-01-03 Sumitovant Biopharma Ltd. By: Marianne L. Romeo Authorized Signatory /s/ Marianne L. Romeo 2020-01-03